Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease

Attila D. Kovács, Angelika Saje, Andrew Wong, G. Szénási, Péter Kiricsi, Éva Szabó, Jonathan D. Cooper, David A. Pearce

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3 Δex1-6) mouse model of the disease displays many pathological characteristics of the human disorder including a deficit in motor coordination. We have previously found that attenuation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptor activity in one-month-old Cln3 Δex1-6 mice resulted in an immediate improvement of their motor skills. Here we show that at a later stage of the disease, in 6-7-month-old Cln3 Δex1-6 mice, acute inhibition of AMPA receptors by a single intraperitoneal injection (1 mg/kg) of the non-competitive AMPA antagonist, EGIS-8332, does not have an immediate effect. Instead, it induces a delayed but prolonged improvement of motor skills. Four days after the injection of the AMPA antagonist, Cln3 Δex1-6 mice reached the same motor skill level as their wild type (WT) counterparts, an improvement that persisted for an additional four days. EGIS-8332 was rapidly eliminated from the brain as measured by HPLC-MS/MS. Histological analysis performed 8 days after the drug administration revealed that EGIS-8332 did not have any impact upon glial activation or the survival of vulnerable neuron populations in 7-month-old Cln3 Δex1-6 mice. We propose that temporary inhibition of AMPA receptors can induce a prolonged correction of the pre-existing abnormal glutamatergic neurotransmission in vivo for juvenile Batten disease.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalNeuropharmacology
Volume60
Issue number2-3
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Neuronal Ceroid-Lipofuscinoses
AMPA Receptors
Motor Skills
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Glutamate Receptors
Vulnerable Populations
Intraperitoneal Injections
Synaptic Transmission
Neuroglia
Neurodegenerative Diseases
High Pressure Liquid Chromatography
Inhibition (Psychology)
Pediatrics
Neurons
Mutation
Injections
Brain
Pharmaceutical Preparations
Genes
EGIS-8332

Keywords

  • AMPA receptor
  • Cln3
  • EGIS-8332
  • Juvenile Batten disease
  • Neuronal ceroid lipofuscinoses
  • Rotarod

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. / Kovács, Attila D.; Saje, Angelika; Wong, Andrew; Szénási, G.; Kiricsi, Péter; Szabó, Éva; Cooper, Jonathan D.; Pearce, David A.

In: Neuropharmacology, Vol. 60, No. 2-3, 02.2011, p. 405-409.

Research output: Contribution to journalArticle

Kovács, Attila D. ; Saje, Angelika ; Wong, Andrew ; Szénási, G. ; Kiricsi, Péter ; Szabó, Éva ; Cooper, Jonathan D. ; Pearce, David A. / Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. In: Neuropharmacology. 2011 ; Vol. 60, No. 2-3. pp. 405-409.
@article{493f51220f9c455fb55e2354be255cae,
title = "Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease",
abstract = "Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3 Δex1-6) mouse model of the disease displays many pathological characteristics of the human disorder including a deficit in motor coordination. We have previously found that attenuation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptor activity in one-month-old Cln3 Δex1-6 mice resulted in an immediate improvement of their motor skills. Here we show that at a later stage of the disease, in 6-7-month-old Cln3 Δex1-6 mice, acute inhibition of AMPA receptors by a single intraperitoneal injection (1 mg/kg) of the non-competitive AMPA antagonist, EGIS-8332, does not have an immediate effect. Instead, it induces a delayed but prolonged improvement of motor skills. Four days after the injection of the AMPA antagonist, Cln3 Δex1-6 mice reached the same motor skill level as their wild type (WT) counterparts, an improvement that persisted for an additional four days. EGIS-8332 was rapidly eliminated from the brain as measured by HPLC-MS/MS. Histological analysis performed 8 days after the drug administration revealed that EGIS-8332 did not have any impact upon glial activation or the survival of vulnerable neuron populations in 7-month-old Cln3 Δex1-6 mice. We propose that temporary inhibition of AMPA receptors can induce a prolonged correction of the pre-existing abnormal glutamatergic neurotransmission in vivo for juvenile Batten disease.",
keywords = "AMPA receptor, Cln3, EGIS-8332, Juvenile Batten disease, Neuronal ceroid lipofuscinoses, Rotarod",
author = "Kov{\'a}cs, {Attila D.} and Angelika Saje and Andrew Wong and G. Sz{\'e}n{\'a}si and P{\'e}ter Kiricsi and {\'E}va Szab{\'o} and Cooper, {Jonathan D.} and Pearce, {David A.}",
year = "2011",
month = "2",
doi = "10.1016/j.neuropharm.2010.10.010",
language = "English",
volume = "60",
pages = "405--409",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "2-3",

}

TY - JOUR

T1 - Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease

AU - Kovács, Attila D.

AU - Saje, Angelika

AU - Wong, Andrew

AU - Szénási, G.

AU - Kiricsi, Péter

AU - Szabó, Éva

AU - Cooper, Jonathan D.

AU - Pearce, David A.

PY - 2011/2

Y1 - 2011/2

N2 - Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3 Δex1-6) mouse model of the disease displays many pathological characteristics of the human disorder including a deficit in motor coordination. We have previously found that attenuation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptor activity in one-month-old Cln3 Δex1-6 mice resulted in an immediate improvement of their motor skills. Here we show that at a later stage of the disease, in 6-7-month-old Cln3 Δex1-6 mice, acute inhibition of AMPA receptors by a single intraperitoneal injection (1 mg/kg) of the non-competitive AMPA antagonist, EGIS-8332, does not have an immediate effect. Instead, it induces a delayed but prolonged improvement of motor skills. Four days after the injection of the AMPA antagonist, Cln3 Δex1-6 mice reached the same motor skill level as their wild type (WT) counterparts, an improvement that persisted for an additional four days. EGIS-8332 was rapidly eliminated from the brain as measured by HPLC-MS/MS. Histological analysis performed 8 days after the drug administration revealed that EGIS-8332 did not have any impact upon glial activation or the survival of vulnerable neuron populations in 7-month-old Cln3 Δex1-6 mice. We propose that temporary inhibition of AMPA receptors can induce a prolonged correction of the pre-existing abnormal glutamatergic neurotransmission in vivo for juvenile Batten disease.

AB - Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3 Δex1-6) mouse model of the disease displays many pathological characteristics of the human disorder including a deficit in motor coordination. We have previously found that attenuation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptor activity in one-month-old Cln3 Δex1-6 mice resulted in an immediate improvement of their motor skills. Here we show that at a later stage of the disease, in 6-7-month-old Cln3 Δex1-6 mice, acute inhibition of AMPA receptors by a single intraperitoneal injection (1 mg/kg) of the non-competitive AMPA antagonist, EGIS-8332, does not have an immediate effect. Instead, it induces a delayed but prolonged improvement of motor skills. Four days after the injection of the AMPA antagonist, Cln3 Δex1-6 mice reached the same motor skill level as their wild type (WT) counterparts, an improvement that persisted for an additional four days. EGIS-8332 was rapidly eliminated from the brain as measured by HPLC-MS/MS. Histological analysis performed 8 days after the drug administration revealed that EGIS-8332 did not have any impact upon glial activation or the survival of vulnerable neuron populations in 7-month-old Cln3 Δex1-6 mice. We propose that temporary inhibition of AMPA receptors can induce a prolonged correction of the pre-existing abnormal glutamatergic neurotransmission in vivo for juvenile Batten disease.

KW - AMPA receptor

KW - Cln3

KW - EGIS-8332

KW - Juvenile Batten disease

KW - Neuronal ceroid lipofuscinoses

KW - Rotarod

UR - http://www.scopus.com/inward/record.url?scp=78650809690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650809690&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.10.010

DO - 10.1016/j.neuropharm.2010.10.010

M3 - Article

VL - 60

SP - 405

EP - 409

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2-3

ER -